The combined use of SGLT2 inhibitors (dapagliflozin or empagliflozin) and conventional diuretics in patients with heart failure reduced the composite outcomes of cardiovascular death or worsening heart failure events [58,59]. Here, SLC5A2 is linked to heart failure.